Method for treating tumors with Anti-her3 antibody drug conjugate and Anti-VEGF antibody

Abstract

A method for treat tumors with an anti-HER3 antibody drug conjugate and an anti-VEGF antibody. In particular, the present invention relates to the use of an anti-HER3 antibody drug conjugate in combination with a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors and the use of a combination of an anti-HER3 antibody drug conjugate and a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors.

Description

Method for treating tumors with anti-HER3 antibody-drug conjugates and anti-VEGF antibodies

[0001] This application claims priority to Chinese patent application No. 202311580719.2 filed on November 24, 2023. This application incorporates the entire text of the aforementioned Chinese patent application. Technical Field

[0002] The present disclosure belongs to the field of medicine and relates to methods and medical uses of anti-HER3 antibody-drug conjugates and anti-VEGF antibodies for treating tumors. Background Art

[0003] HER3 (epidermal growth factor receptor 3, ErbB-3 or HER3) is a member of the epidermal growth factor receptor (EGFR) family. This family includes HER1 (erbB1, EGFR), HER2 (erbB2, NEU), HER3 (erbB3), and HER4 (erbB4). These receptors all contain three parts: an extracellular region, a transmembrane region, and an intracellular region. The extracellular region contains four domains, and the intracellular region contains an intracellular tyrosine kinase domain for signal transduction and a tail with tyrosine phosphorylation residues located in the cytoplasm. When ligands bind to extracellular domains I and III, cell signaling is initiated. Under normal circumstances, these receptors mediate cell division, migration, survival, and organ development. When EGFR family members mutate, the resulting abnormal signaling stimulates cell survival and is associated with cancer progression. The basic mechanism by which the HER3 receptor is activated and produces its physiological effects is similar to that of other HER3 family members. However, its ligands include neuregulin 1 (NRG-1) and neuregulin 2 (NRG-2). Furthermore, upon activation, HER3 cannot form homomers, but can only form heterodimers with EGFR or HER2. During heterodimerization, the intracellular domain of HER3 exhibits high tyrosine phosphatase activity. Structural analysis has revealed six P85 (PI-3K) binding sites within the HER3 intracellular domain. This specific structure enables HER3 to recruit up to six PI-3Ks to the P85 regulatory subunit upon interaction, thereby strongly activating the PI-3K signaling pathway. In fact, the HER3 / HER2 dimer is the most active of the HER3 dimers. EGFR is widely distributed on the surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, and other cells. The EGFR signaling pathway plays a crucial role in physiological processes such as cell growth, proliferation, and differentiation.

[0004] Antibody-drug conjugates (ADCs) covalently attach a cytotoxic small molecule drug to an antibody via a chemical linker. Using the antibody as a carrier, the small molecule drug is delivered to target cells. ADCs combine the highly targeted properties of antibodies with the potent killing power of cytotoxic drugs against target cells, thereby improving the effectiveness of chemotherapy and reducing systemic exposure and toxicity. The HER3 receptor has a much higher internalization efficiency than other members of the HER3 receptor family, making it a more suitable target for ADC drugs.

[0005] Developing safe and effective clinical treatment strategies targeting HER3 is an important issue that needs to be addressed in this field. Summary of the Invention

[0006] The present disclosure provides methods and medical uses of anti-HER3 antibody-drug conjugates for treating tumors.

[0007] In a first aspect, the present disclosure provides use of an anti-HER3 antibody-drug conjugate combined with a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors.

[0008] In a second aspect, the present disclosure provides use of a combination of an anti-HER3 antibody-drug conjugate and a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors.

[0009] In a third aspect, the present disclosure provides use of a pharmaceutical composition in preparing a drug for treating tumors, wherein the pharmaceutical composition comprises an anti-HER3 antibody-drug conjugate and a VEGF signaling pathway inhibitor.

[0010] In a fourth aspect, the present disclosure provides a method for treating a subject having a tumor, comprising administering to the subject: an anti-HER3 antibody drug conjugate; and a VEGF signaling pathway inhibitor.

[0011] In a fifth aspect, the present disclosure provides an anti-HER3 antibody-drug conjugate for use in treating a subject suffering from a tumor; wherein the subject is also receiving treatment with a VEGF signaling pathway inhibitor.

[0012] In a sixth aspect, the present disclosure provides an anti-HER3 antibody-drug conjugate combined with a VEGF signaling pathway inhibitor for use in treating tumors.

[0013] In a seventh aspect, the present disclosure provides a VEGF signaling pathway inhibitor for use in treating a subject having a tumor, wherein the subject is also administered an anti-HER3 antibody-drug conjugate.

[0014] In an eighth aspect, the present disclosure provides a pharmaceutical composition comprising an anti-HER3 antibody-drug conjugate and a VEGF signaling pathway inhibitor.

[0015] In some embodiments, as described in the first to seventh aspects above, the tumor is a solid tumor. In some embodiments, the tumor is non-small cell lung cancer. In some specific embodiments, the tumor is non-squamous non-small cell lung cancer. In some embodiments, the tumor includes but is not limited to any one or any combination of the following:

[0016] (1) Locally advanced or metastatic solid tumors (e.g., locally advanced or metastatic NSCLC);

[0017] (2) locally advanced or metastatic nonsquamous cell carcinoma (e.g., locally advanced or metastatic nonsquamous cell NSCLC);

[0018] (3) Advanced or metastatic solid tumors that have relapsed or progressed after standard treatment, or for which there is no standard treatment option or standard treatment is not currently applicable;

[0019] (4) Unresectable locally advanced or metastatic solid tumors that have recurred or progressed after standard treatment, or for which there is no standard treatment option or standard treatment is not currently applicable;

[0020] (5) EGFR-mutated tumors (e.g., EGFR-mutated NSCLC);

[0021] (6) The subject with the tumor has a history of treatment with a tyrosine kinase inhibitor (TKI);

[0022] (7) Tumors that have failed EGFR-TKI treatment (e.g., NSCLC that has failed EGFR-TKI treatment).

[0023] In some embodiments, "locally advanced or metastatic NSCLC" refers to a subject with histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer. In some specific embodiments, "locally advanced or metastatic NSCLC" refers to a subject with histologically or cytologically confirmed unresectable locally advanced or metastatic non-small cell lung cancer. Exemplarily, the histological or cytological confirmation results are based on treatment guidelines such as CSCO, NCCN, and ESMO.

[0024] In some specific embodiments, "locally advanced or metastatic NSCLC" refers to a subject with histologically or cytologically confirmed unresectable locally advanced or metastatic non-squamous non-small cell lung cancer.

[0025] In some embodiments, the terms "EGFR mutation" and "EGFR mutation positive" are used interchangeably, and may refer to either a sensitizing mutation or a non-sensitizing mutation. In some embodiments, the "EGFR mutation" is exon 19 deletion (19del) and exon 21 L858R mutation (L858R), or other mutations (e.g., G719X, L861Q, etc.).

[0026] In the present disclosure, standard treatment regimens are well known to those skilled in the art, for example, treatment regimens disclosed in treatment guidelines approved by regulatory authorities, including but not limited to detailed and up-to-date information on standard treatment regimens for various cancers provided in the NCCN Guidelines and the CSCO Guidelines.

[0027] Anti-HER3 Antibody Drug Conjugates

[0028] In some embodiments, the anti-HER3 antibody drug conjugate is derived from an antibody drug conjugate of any structure in WO2022078425A1 and WO2020063676A1. The present disclosure incorporates the structures, preparation methods, and other related contents of the immunoconjugates in the above patents into the present disclosure by reference.

[0029] In some embodiments, the anti-HER3 antibody drug conjugate has a structure as shown in the following formula:

[0030] Wherein: n is 1 to 8, n is a decimal or an integer; Pc is an anti-HER3 antibody.

[0031] In some embodiments, n is 4.0±0.4.

[0032] In this disclosure, "antibody" is used in the broadest sense to cover various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies or antigen-binding fragments thereof (also referred to as "antigen-binding portions"), so long as they exhibit the desired antigen-binding activity.

[0033] In some embodiments, the anti-HER3 antibody is derived from any type of anti-HER3 antibody or antigen-binding fragment thereof in WO2022078425A1. The present disclosure incorporates the antibody sequences, preparation methods and other related contents in the above patents into the present disclosure by reference.

[0034] In some embodiments, the anti-HER3 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively; and / or the light chain variable region comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively.

[0035] The aforementioned CDR sequences are shown in the following table:

[0036] Table 1. CDR sequences obtained by Kabat numbering rules

[0037] The CDRs are defined according to the Kabat numbering system.

[0038] In some embodiments, the anti-HER3 antibody comprises any one, any two, any three, any four, any five, or six CDRs selected from HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO: 1 to SEQ ID NO: 6.

[0039] In some embodiments, the anti-HER3 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, respectively, as shown in SEQ ID NO: 7, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, respectively, as shown in SEQ ID NO: 8. The CDRs are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering systems. In some specific embodiments, the CDRs are defined according to the Kabat numbering system.

[0040] In some embodiments, an anti-HER3 antibody-drug conjugate and an anti-VEGF antibody or an antigen-binding fragment thereof are used in combination to prepare a medicament for treating tumors. The VH of the anti-HER3 antibody comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 1-3, and the VL of the anti-HER3 antibody or an antigen-binding fragment thereof comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 4-6.

[0041] In some embodiments, the anti-HER3 antibody is a murine antibody, a chimeric antibody, a humanized antibody, a human antibody, or an antigen-binding fragment thereof. In some specific embodiments, the anti-HER3 antibody is selected from a humanized antibody or an antigen-binding fragment thereof.

[0042] In some embodiments, the VH of the anti-HER3 antibody comprises the amino acid sequence as shown in SEQ ID NO: 7, or an amino acid sequence having at least 80% sequence identity thereto; and the VL comprises the amino acid sequence as shown in SEQ ID NO: 8, or an amino acid sequence having at least 80% sequence identity thereto.

[0043] HER3 heavy chain variable region:

[0044] HER3 light chain variable region:

[0045] In some embodiments, the anti-HER3 antibody comprises any one or two of the above-mentioned VH and VL.

[0046] In some embodiments, the anti-HER3 antibody further comprises an antibody constant region; for example, the heavy chain constant region of the antibody constant region is selected from human IgG1, IgG2, IgG3 and IgG4 constant regions and variants thereof; the light chain constant region of the antibody constant region is selected from human antibody κ and λ chain constant regions and variants thereof.

[0047] The above light chain variable region and light chain constant region sequences are combined to form a light chain sequence, and each heavy chain variable region and heavy chain constant region are combined to form a heavy chain sequence. An exemplary humanized antibody sequence is shown below:

[0048] HER3-29 heavy chain:

[0049] HER3-29 light chain:

[0050] In some embodiments, the anti-HER3 antibody comprises a heavy chain and a light chain, wherein the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO:9, or at least 80% identical thereto, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO:10, or at least 80% identical thereto.

[0051] In some embodiments, the anti-HER3 antibody comprises any one or two of the aforementioned heavy and light chains.

[0052] In some embodiments, an anti-HER3 antibody-drug conjugate and an anti-VEGF antibody are used in combination to prepare a medicament for treating tumors, wherein the heavy chain of the anti-HER3 antibody comprises the amino acid sequence shown in SEQ ID NO: 9, and the light chain comprises the amino acid sequence shown in SEQ ID NO: 10.

[0053] In the context of the present disclosure, "at least 80%" and "at least 90%" encompass 80% and above, for example at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, and any numerical range therebetween.

[0054] In some embodiments, the anti-HER3 antibody drug conjugate is administered at a dose of about 0.1 mg / kg to about 20 mg / kg, for example, about 1.0 mg / kg to about 20 mg / kg, about 1.0 mg / kg to about 12 mg / kg, about 1.0 mg / kg to about 10.5 mg / kg, about 1.0 mg / kg to about 10 mg / kg, about 1.0 mg / kg to about 9 mg / kg, about 1.0 mg / kg to about 8.5 mg / kg, about 1.0 mg / kg to about 8.0 mg / kg; about 1.5 mg / kg to about 10.5 mg, about 1.5 mg / kg to about 9.0 mg / kg, about 1.5 mg / kg to about 8.5 mg / kg, about 1.5 mg / kg to about 8.0 mg / kg, about 1.5 mg / kg to about 7.5 mg / kg. g / kg; about 3.0 mg / kg to about 9.0 mg / kg; about 4.5 mg / kg to about 9.0 mg / kg; about 6.0 mg / kg to about 9.0 mg / kg; about 7.5 mg / kg to about 9.0 mg / kg; about 3.0 mg / kg to about 8.5 mg / kg; about 4.5 mg / kg to about 8.5 mg / kg; about 6.0 mg / kg to about 8.5 mg / kg; about 7.5 mg / kg to about 8.5 mg / kg; about 3.0 mg / kg to about 8.0 mg / kg; about 4.5 mg / kg to about 8.0 mg / kg; about 6.0 mg / kg to about 8.0 mg / kg; about 7.5 mg / kg to about 8.0 mg / kg; about 3.0 mg / kg to about 7.5 mg / kg, or any range therebetween.

[0055] In some embodiments, the anti-HER3 antibody drug conjugate is administered at a dose selected from about 1.0 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, about 1.3 mg / kg, about 1.4 mg / kg, about 1.5 mg / kg, about 1.6 mg / kg, about 1.7 mg / kg, about 1.8 mg / kg, about 1.9 mg / kg, about 2.0 mg / kg, about 2.1 mg / kg, about 2.2 mg / kg, about 2.3 mg / kg, about 2.4 mg / kg, about 2.5 mg / kg, about 2.6 mg / kg, about 2.7 mg / kg, about 2.8 mg / kg, about 2.9 mg / kg, about 3.0 mg / kg, about 3.1 mg / kg, about 3.2 mg / kg, about 3.4 mg / kg, about 3.5 mg / kg, about 3.6 mg / kg, about 3.8 mg / kg, about 4.0 mg / kg, about 4.2 mg / kg, about 4.3 mg / kg, about 4.5 mg / kg, about 4.6 mg / kg, about 4.8 mg / kg, about 5.0 mg / kg g, about 5.1 mg / kg, about 5.3 mg / kg, about 5.5 mg / kg, about 5.6 mg / kg, about 5.8 mg / kg, about 6.0 mg / kg, about 6.1 mg / kg, about 6.3 mg / kg, about 6.4 mg / kg, about 6.5 mg / kg, about 6.6 mg / kg, about 6.8 mg / kg, about 6.9 mg / kg, about 7.0 mg / kg, about 7.2 mg / kg, about 7.4 mg / kg, about 7.5 mg / kg, about 7.6 mg / kg, about 7 .8mg / kg, about 8.0mg / kg, about 8.1mg / kg, about 8.3mg / kg, about 8.5mg / kg, about 8.8mg / kg, about 9.0mg / kg, about 9.5mg / kg, about 10.0mg / kg, about 10.5mg / kg, about 12mg / kg, about 12.5mg / kg, about 13mg / kg, about 13.5mg / kg, about 14mg / kg, about 16mg / kg, about 18mg / kg, about 19mg / kg, about 20mg / kg.

[0056] In some embodiments, the anti-HER3 antibody drug conjugate is administered once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every 12 weeks. In some specific embodiments, the anti-HER3 antibody drug conjugate is administered once every three weeks.

[0057] In some embodiments, the administration regimen of the anti-HER3 antibody drug conjugate is selected from any one of the following:

[0058] (a1) a dose of about 0.1 mg / kg to about 20 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0059] (a2) the dosage is about 1.0 mg / kg to about 13.5 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0060] (a3) the dosage is about 1.0 mg / kg to about 10.5 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0061] (a4) the dosage is about 1.0 mg / kg to about 9.0 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0062] (a5) the dosage is about 1.0 mg / kg to about 8.5 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0063] (a6) the dosage is about 1.0 mg / kg to about 8.0 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0064] (a7) the dosage is about 1.5 mg / kg to about 10.5 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0065] (a8) the dosage is about 1.5 mg / kg to about 9.0 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0066] (a9) the dosage is about 1.5 mg / kg to about 8.5 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0067] (a 10 ) the dosage is about 1.5 mg / kg to about 8.0 mg / kg, and the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0068] (a11 ) the dosage is about 2 mg / kg to about 9.0 mg / kg, and the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0069] (a 12 ) the dosage is about 2 mg / kg to about 8.0 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0070] (a 13 ) the dosage is about 4 mg / kg to about 9.0 mg / kg, and the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0071] (a 14 ) the dosage is about 4 mg / kg to about 8.0 mg / kg, and the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0072] (a 15 ) the dosage is about 5 mg / kg to about 9.0 mg / kg, and the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0073] (a 16 ) the dosage is about 5 mg / kg to about 8.0 mg / kg, and the administration frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0074] (a 17 ) the dosage is about 6 mg / kg to about 9.0 mg / kg, and the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0075] (a 18 ) the dosage is about 6 mg / kg to about 8.0 mg / kg, and the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0076] (a 19) about 1.0 mg / kg, about 1.5 mg / kg, about 3.0 mg / kg, about 4.5 mg / kg, about 5.0 mg / kg, about 5.5 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7 mg / kg, about 7.5 mg / kg, about 8.0 mg / kg, about 8.5 mg / kg, about 9.0 mg / kg, about 10.5 mg / kg, about 12 mg / kg, about 13.5 mg / kg; the dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks;

[0077] (a 20 ) The dosage of the anti-HER3 antibody drug conjugate is about 1.5 mg / kg, and the administration frequency is once every three weeks;

[0078] (a 21 ) The dosage of the anti-HER3 antibody drug conjugate is about 3.0 mg / kg, and the administration frequency is once every three weeks;

[0079] (a 22 ) The dosage of the anti-HER3 antibody drug conjugate is about 4.5 mg / kg, and the administration frequency is once every three weeks;

[0080] (a 23 ) The dosage of the anti-HER3 antibody drug conjugate is about 5.0 mg / kg, and the administration frequency is once every three weeks;

[0081] (a 24 ) The dosage of the anti-HER3 antibody drug conjugate is about 5.5 mg / kg, and the administration frequency is once every three weeks;

[0082] (a 25 ) The dosage of the anti-HER3 antibody drug conjugate is about 6.0 mg / kg, and the administration frequency is once every three weeks;

[0083] (a 26 ) The dosage of the anti-HER3 antibody drug conjugate is about 7.0 mg / kg, and the administration frequency is once every three weeks;

[0084] (a 27 ) The dosage of the anti-HER3 antibody drug conjugate is about 7.5 mg / kg, and the administration frequency is once every three weeks;

[0085] (a 28 ) The dosage of the anti-HER3 antibody drug conjugate is about 8.0 mg / kg, and the administration frequency is once every three weeks;

[0086] (a 29) The dosage of the anti-HER3 antibody drug conjugate is about 8.5 mg / kg, and the administration frequency is once every three weeks;

[0087] (a 30 ) The dosage of the anti-HER3 antibody drug conjugate is about 9.0 mg / kg, and the administration frequency is once every three weeks.

[0088] In some specific embodiments, in the above (a1)-(a 19 ) In any one of the dosage regimens described above, the anti-HER3 antibody drug conjugate is administered once every three weeks.

[0089] VEGF signaling pathway inhibitors

[0090] In some embodiments, the VEGF signaling pathway inhibitor includes a VEGF ligand inhibitor, and a VEGF receptor inhibitor. In some embodiments, the VEGF signaling pathway inhibitor is an anti-VEGF antibody.

[0091] In this disclosure, "antibody" is used in the broadest sense to cover various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies or antigen-binding fragments thereof (also referred to as "antigen-binding portions"), so long as they exhibit the desired antigen-binding activity.

[0092] In some embodiments, the anti-VEGF antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 11-13, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 14-16.

[0093] Among them, the CDR sequences mentioned above are shown in the following table:

[0094] Table 2. CDR sequences of anti-VEGF antibodies

[0095] The above-mentioned CDRs are defined according to the Kabat, IMGT, Chothia, AbM or Contact definition schemes. In some specific embodiments, the CDRs are defined according to the Kabat definition scheme.

[0096] In some embodiments, the anti-VEGF antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL): wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 11-13, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 14-16.

[0097] In some embodiments, an anti-HER3 antibody drug conjugate is used in combination with an anti-VEGF antibody or an antigen-binding fragment thereof for the preparation of a medicament for treating tumors, wherein the VH of the anti-VEGF antibody comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 11-13, and the VL of the anti-VEGF antibody or an antigen-binding fragment thereof comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 14-16.

[0098] In some embodiments, the anti-VEGF antibody or antigen-binding fragment thereof is a chimeric, humanized, fully human antibody or antigen-binding fragment thereof.

[0099] In some embodiments, the anti-VEGF antibody or antigen-binding fragment thereof, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 17, or an amino acid sequence having at least 80% or 90% sequence identity thereto; the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 18, or an amino acid sequence having at least 80% or 90% sequence identity thereto.

[0100] Heavy chain variable region:

[0101] Light chain variable region:

[0102] In some embodiments, the heavy chain variable region of the anti-VEGF antibody comprises an amino acid sequence as set forth in SEQ ID NO: 17, or at least 80% identical thereto, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 18, or at least 80% identical thereto.

[0103] In some embodiments, the anti-VEGF antibody further comprises a heavy chain constant region and / or a light chain constant region, for example, the heavy chain constant region of the antibody constant region is selected from human IgG1, IgG2, IgG3 and IgG4 constant regions and variants thereof; the light chain constant region of the antibody constant region is selected from human antibody κ and λ chain constant regions and variants thereof.

[0104] In some embodiments, the anti-VEGF antibody comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 19, or at least 80% identical thereto; and / or the light chain comprising an amino acid sequence as set forth in SEQ ID NO: 20, or at least 80% identical thereto.

[0105] In some embodiments, the anti-VEGF antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO: 19, and a light chain having an amino acid sequence as shown in SEQ ID NO: 20.

[0106] Heavy chain sequence of anti-VEGF antibody:

[0107] Light chain sequence of anti-VEGF antibody:

[0108] Note: The underlined portion is the variable region sequence of the antibody heavy chain or light chain, and the ununderlined portion is the antibody constant region sequence.

[0109] In some embodiments, an anti-HER3 antibody-drug conjugate and an anti-VEGF antibody are used in combination to prepare a medicament for treating tumors, wherein the heavy chain of the anti-VEGF antibody comprises the amino acid sequence shown in SEQ ID NO: 19, and the light chain comprises the amino acid sequence shown in SEQ ID NO: 20.

[0110] In some embodiments, the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 30 mg / kg, for example, about 2.0 mg / kg to about 25 mg / kg, about 2.0 mg / kg to about 20 mg / kg, about 2.0 mg / kg to about 19 mg / kg, about 2.0 mg / kg to about 18 mg / kg, about 2.0 mg / kg to about 17 mg / kg, about 2.0 mg / kg to about 16 mg / kg, about 2.0 mg / kg to about 15 mg / kg, about 3.0 mg / kg to about 25 mg / kg, about 3.0 mg / kg to about 20 mg / kg, about 3.0 mg / kg to about 19 mg / kg, about 3.0 mg / kg to about 25 mg / kg. .0 mg / kg to about 18 mg / kg, about 3.0 mg / kg to about 17 mg / kg, about 3.0 mg / kg to about 16 mg / kg, about 3.0 mg / kg to about 15 mg / kg, about 4.0 mg / kg to about 25 mg / kg, about 4.0 mg / kg to about 20 mg / kg, about 4.0 mg / kg to about 19 mg / kg, about 4.0 mg / kg to about 18 mg / kg, about 4.0 mg / kg to about 17 mg / kg, about 4.0 mg / kg to about 16 mg / kg, about 4.0 mg / kg to about 15 mg / kg, about 5.0 mg / kg to about 25 mg / kg, about 5.0 mg / kg to about 20 mg / kg, about 5.0 mg / kg to about 19 mg / kg, about 5.0 mg / kg to about 18 mg / kg, about 5.0 mg / kg to about 17 mg / kg, about 5.0 mg / kg to about 16 mg / kg, about 5.0 mg / kg to about 15 mg / kg, about 6.0 mg / kg to about 25 mg / kg, about 6.0 mg / kg to about 20 mg / kg, about 6.0 mg / kg to about 19 mg / kg, about 6.0 mg / kg to about 18 mg / kg, about 6.0 mg / kg to about 17 mg / kg, about 6.0 mg / kg to about 16 mg / kg, about 6.0 mg / kg to about 15 mg / kg, about 7.0 or any range therebetween.

[0111] In some embodiments, the anti-VEGF antibody is administered at a dose selected from about 2.0 mg / kg, about 3.0 mg / kg, about 4.0 mg / kg, about 5.0 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7.0 mg / kg, about 7.5 mg / kg, 8.0 mg / kg, 8.5 mg / kg, about 9.0 mg / kg, about 9.5 mg / kg, about 10.0 mg / kg, about 10.5 mg / kg, about 11.0 mg / kg, about 11.5 mg / kg, about 12.0 mg / kg, about 12.5 mg / kg, about 13.0 mg / kg, about 13.5 mg / kg, about 14.0 mg / kg, about 14.5 mg / kg, about 15.0 mg / kg, about 15.5 mg / kg, about 16.0 mg / kg, about 16.5 mg / kg, about 17.0 mg / kg, about 18.0 mg / kg, about 19.0 mg / kg, about 20.0 mg / kg, about 21.0 mg / kg, about 22.0 mg / kg, about 23.0 mg / kg, about 24.0 mg / kg, about 25.0 mg / kg, about 30.0 mg / kg.

[0112] In some embodiments, the anti-VEGF antibody is administered once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every 12 weeks. In some specific embodiments, the anti-VEGF antibody is administered once every three weeks.

[0113] In some embodiments, the dosing regimen of the anti-VEGF antibody is selected from any one of the following:

[0114] (c1) the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 30 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0115] (c2) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 20 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0116] (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0117] (c4) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 18 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0118] (c5) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 17 mg / kg, and the administration frequency is once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0119] (c6) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 16 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0120] (c7) the anti-VEGF antibody is administered at a dose of about 3.0 mg / kg to about 20 mg / kg, and the administration frequency is once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0121] (c8) the anti-VEGF antibody is administered at a dose of about 3.0 mg / kg to about 19 mg / kg, and the administration frequency is once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0122] (c9) the anti-VEGF antibody is administered at a dose of about 3.0 mg / kg to about 18 mg / kg, and the administration frequency is once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0123] (c 10 ) the anti-VEGF antibody is administered at a dose of about 3.0 mg / kg to about 17 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0124] (c 11 ) the anti-VEGF antibody is administered at a dose of about 3.0 mg / kg to about 16 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0125] (c 12) the anti-VEGF antibody is administered at a dose of about 4.0 mg / kg to about 20 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0126] (c 13 ) the anti-VEGF antibody is administered at a dose of about 4.0 mg / kg to about 19 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0127] (c 14 ) the anti-VEGF antibody is administered at a dose of about 4.0 mg / kg to about 18 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0128] (c 15 ) The anti-VEGF antibody is administered at a dose of about 2.0 mg / kg, about 3.0 mg / kg, about 4.0 mg / kg, about 5.0 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7.0 mg / kg, about 7.5 mg / kg, 8.0 mg / kg, 8.5 mg / kg, about 9.0 mg / kg, about 9.5 mg / kg, about 10.0 mg / kg, about 10.5 mg / kg, about 11.0 mg / kg, about 11.5 mg / kg, about 12.0 mg / kg, about 12.5 mg / kg, about 13.0 mg / kg, about 13.5 mg / kg, about 14.0 mg / kg, about 14.5 mg / kg, about 15.0 mg / kg, about 15.5 mg / kg, about 16.0 mg / kg, about 16.5 mg / kg, about 17.0 mg / kg, about 18.0 mg / kg, about 19.0 mg / kg, about 20.0 mg / kg, about 21.0 mg / kg, about 22.0 mg / kg, about 23.0 mg / kg, about 24.0 mg / kg, about 25.0 mg / kg, about 30.0 mg / kg; dosing frequency is selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0129] (c 16 ) The anti-VEGF antibody is administered at a dose of about 6.0 mg / kg, and the administration frequency is once every three weeks;

[0130] (c 17 ) The anti-VEGF antibody is administered at a dose of about 6.5 mg / kg, with a frequency of once every three weeks;

[0131] (c18 ) The anti-VEGF antibody is administered at a dose of about 7.0 mg / kg, and the administration frequency is once every three weeks;

[0132] (c 19 ) The anti-VEGF antibody is administered at a dosage of about 7.5 mg / kg, and the administration frequency is once every three weeks;

[0133] (c 20 ) The anti-VEGF antibody is administered at a dose of about 8.0 mg / kg, and the administration frequency is once every three weeks;

[0134] (c 21 ) The anti-VEGF antibody is administered at a dose of about 8.5 mg / kg, with a frequency of once every three weeks;

[0135] (c 22 ) The anti-VEGF antibody is administered at a dose of about 9.0 mg / kg, and the administration frequency is once every three weeks;

[0136] (c 23 ) The anti-VEGF antibody is administered at a dose of about 9.5 mg / kg, with a frequency of once every three weeks;

[0137] (c 24 ) The anti-VEGF antibody is administered at a dosage of about 10.0 mg / kg, and the administration frequency is once every three weeks;

[0138] (c 25 ) The anti-VEGF antibody is administered at a dose of about 10.5 mg / kg, with a frequency of once every three weeks;

[0139] (c 26 ) The anti-VEGF antibody is administered at a dose of about 11.0 mg / kg, and the administration frequency is once every three weeks;

[0140] (c 27 ) The anti-VEGF antibody is administered at a dose of about 11.5 mg / kg, with a frequency of once every three weeks;

[0141] (c 28 ) The anti-VEGF antibody is administered at a dose of about 12.0 mg / kg, with a frequency of once every three weeks;

[0142] (c 29 ) The anti-VEGF antibody is administered at a dose of about 12.5 mg / kg, with a frequency of once every three weeks;

[0143] (c 30 ) The anti-VEGF antibody is administered at a dose of about 13.0 mg / kg, and the administration frequency is once every three weeks;

[0144] (c 31 ) The anti-VEGF antibody is administered at a dose of about 13.5 mg / kg, with a frequency of once every three weeks;

[0145] (c 32 ) The anti-VEGF antibody is administered at a dose of about 14.0 mg / kg, with a frequency of once every three weeks;

[0146] (c 33 ) The anti-VEGF antibody is administered at a dose of about 14.5 mg / kg, with a frequency of once every three weeks;

[0147] (c 34 ) The anti-VEGF antibody is administered at a dose of about 15.0 mg / kg, and the administration frequency is once every three weeks;

[0148] (c 35 ) The anti-VEGF antibody is administered at a dose of about 15.5 mg / kg, with a frequency of once every three weeks;

[0149] (c 36 ) The anti-VEGF antibody is administered at a dose of about 16.0 mg / kg, with a frequency of once every three weeks;

[0150] (c 37 ) The anti-VEGF antibody is administered at a dose of about 17.0 mg / kg, with a dosing frequency of once every three weeks;

[0151] (c 38 ) The dosage of the anti-VEGF antibody is about 18.0 mg / kg, and the administration frequency is once every three weeks.

[0152] In some specific embodiments, in the above (c1)-(c 15 ) In any one of the dosage regimens, the anti-VEGF antibody is administered once every three weeks.

[0153] In some embodiments, the administration regimen of the anti-HER3 antibody drug conjugate combined with the anti-VEGF antibody is selected from any one of the following:

[0154] (a1) the anti-HER3 antibody drug conjugate is administered at a dose of about 0.1 mg / kg to about 20 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks; and (c1) the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 30 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0155] (a2) the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 13.5 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c2) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 20 mg / kg at a frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0156] (a3) the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 10.5 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 0.1 mg / kg to about 3 mg / kg at a frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0157] (a4) the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 9.0 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg at a frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0158] (a5) the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 8.5 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg at a frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0159] (a6) the anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 8.0 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg at a frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0160] (a7) the anti-VEGF antibody is administered at a dose of about 1.5 mg / kg to about 10.5 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg at a frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0161] (a8) the anti-VEGF antibody is administered at a dose of about 1.5 mg / kg to about 9.0 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0162] (a9) the anti-VEGF antibody is administered at a dose of about 1.5 mg / kg to about 8.5 mg / kg at a frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg at a frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0163] (a 10 ) is administered at a dose of about 1.5 mg / kg to about 8.0 mg / kg, with a dosing frequency selected from once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every ten weeks; and (c3) the anti-VEGF antibody is administered at a dose of about 2.0 mg / kg to about 19 mg / kg, with a dosing frequency of once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every twelve weeks;

[0164] The anti-HER3 antibody drug conjugate is administered at a dose of about 3.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks;

[0165] The anti-HER3 antibody drug conjugate is administered at a dose of about 4.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks;

[0166] The anti-HER3 antibody drug conjugate is administered at a dose of about 5.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks.

[0167] The anti-HER3 antibody drug conjugate is administered at a dose of about 5.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks;

[0168] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks.

[0169] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks;

[0170] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks.

[0171] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks.

[0172] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks;

[0173] The anti-HER3 antibody drug conjugate is administered at a dose of about 9.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks.

[0174] The anti-HER3 antibody drug conjugate is administered at a dose of about 10.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 15.0 mg / kg, once every three weeks.

[0175] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 17.0 mg / kg, once every three weeks.

[0176] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 17.0 mg / kg, once every three weeks.

[0177] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 17.0 mg / kg, once every three weeks;

[0178] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 17.0 mg / kg, once every three weeks.

[0179] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 16.0 mg / kg, once every three weeks.

[0180] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 16.0 mg / kg, once every three weeks.

[0181] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 16.0 mg / kg, once every three weeks.

[0182] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 16.0 mg / kg, once every three weeks.

[0183] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 14.0 mg / kg, once every three weeks.

[0184] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 14.0 mg / kg, once every three weeks.

[0185] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 14.0 mg / kg, once every three weeks.

[0186] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 14.0 mg / kg, once every three weeks.

[0187] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 13.0 mg / kg, once every three weeks.

[0188] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 13.0 mg / kg, once every three weeks;

[0189] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 13.0 mg / kg, once every three weeks;

[0190] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 13.0 mg / kg, once every three weeks.

[0191] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 12.0 mg / kg, once every three weeks.

[0192] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 12.0 mg / kg, once every three weeks.

[0193] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 12.0 mg / kg, once every three weeks.

[0194] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 12.0 mg / kg, once every three weeks.

[0195] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 11.0 mg / kg, once every three weeks.

[0196] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 11.0 mg / kg, once every three weeks.

[0197] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 11.0 mg / kg, once every three weeks.

[0198] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 11.0 mg / kg, once every three weeks.

[0199] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 10.0 mg / kg, once every three weeks;

[0200] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 10.0 mg / kg, once every three weeks;

[0201] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 10.0 mg / kg, once every three weeks;

[0202] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 10.0 mg / kg, once every three weeks.

[0203] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 9.0 mg / kg, once every three weeks;

[0204] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 9.0 mg / kg, once every three weeks.

[0205] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 9.0 mg / kg, once every three weeks.

[0206] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 9.0 mg / kg, once every three weeks.

[0207] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 8.0 mg / kg, once every three weeks.

[0208] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 8.0 mg / kg, once every three weeks.

[0209] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 8.0 mg / kg, once every three weeks.

[0210] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, with a dosing frequency of once every three weeks; and the anti-VEGF antibody is administered at a dose of 8.0 mg / kg, with a dosing frequency of once every three weeks;

[0211] The anti-HER3 antibody drug conjugate is administered at a dose of about 6.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 7.5 mg / kg, once every three weeks.

[0212] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 7.5 mg / kg, once every three weeks.

[0213] The anti-HER3 antibody drug conjugate is administered at a dose of about 7.5 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 7.5 mg / kg, once every three weeks.

[0214] The anti-HER3 antibody drug conjugate is administered at a dose of about 8.0 mg / kg, once every three weeks; and the anti-VEGF antibody is administered at a dose of 7.5 mg / kg, once every three weeks.

[0215] In some embodiments, the anti-VEGF antibody is administered orally, parenterally, or transdermally; parenteral administration includes, but is not limited to, intravenous injection, subcutaneous injection, and intramuscular injection. In some specific embodiments, the anti-VEGF antibody is administered intravenously.

[0216] In some embodiments, the anti-HER3 antibody drug conjugate is administered orally, parenterally, or transdermally; parenteral administration includes, but is not limited to, intravenous injection, subcutaneous injection, and intramuscular injection. In some specific embodiments, the anti-HER3 antibody drug conjugate is administered by intravenous injection.

[0217] In some embodiments, the anti-HER3 antibody drug conjugate is formulated in an injectable form. Exemplarily, the injectable form of the anti-HER3 antibody drug conjugate is an injection solution or a lyophilized powder injection, which comprises the anti-HER3 antibody drug conjugate and one or more pharmaceutically acceptable excipients.

[0218] In some embodiments, the pharmaceutical composition comprising an anti-HER3 antibody drug conjugate further comprises a buffer, a stabilizer, an osmotic pressure regulator and / or a surfactant. Exemplarily, the buffer is selected from any one of acetic acid-sodium acetate, succinic acid-sodium succinate, histidine-hydrochloride and citric acid-sodium citrate buffer. In some specific embodiments, the buffer is acetic acid-sodium acetate. Exemplarily, the surfactant may be selected from polysorbates (e.g., polysorbate 20, polysorbate 80), polyhydroxyalkylene, Triton, sodium dodecyl sulfate, sodium lauryl sulfate, sodium octyl glucoside, lauryl-sulfobetaine, myristyl-sulfobetaine, linoleyl-sulfobetaine, stearyl-sulfobetaine, lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine, stearyl-sarcosine, linoleyl-betaine, myristyl-betaine, spermaceti In some specific embodiments, the surfactant is a polysorbate. Exemplary are polysorbate 80 or polysorbate 20. In some specific embodiments, the surfactant is polysorbate 80. In some embodiments, the pharmaceutical composition comprising an anti-HER3 antibody drug conjugate further comprises a sugar. Exemplary, "sugar" comprises a conventional composition (CHO). n and derivatives thereof, including monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, non-reducing sugars, and the like. The sugar can be selected from glucose, sucrose, trehalose, α,α-trehalose dihydrate, lactose, fructose, maltose, dextran, glycerol, erythritol, glycerol, arabitol, sylitol, sorbitol, mannitol, melibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, sorbitol, maltitol, lactitol, iso-maltulose, and the like. In some specific embodiments, the "sugar" is sucrose.

[0219] In some embodiments, the order of administration of the anti-HER3 antibody drug conjugate combined with the anti-VEGF antibody is: anti-HER3 antibody drug conjugate, then anti-VEGF antibody, with the required time interval between the two administrations (e.g., at least 30 minutes, at least 1 hour, at least 2 hours, etc.).

[0220] In some embodiments, the order of administration of the anti-HER3 antibody drug conjugate combined with the anti-VEGF antibody is: anti-VEGF antibody, then anti-HER3 antibody drug conjugate, with the required time interval between the administration of the two (e.g., at least 30 minutes, at least 1 hour, at least 2 hours, etc.).

[0221] the term

[0222] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise explicitly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present disclosure belongs.

[0223] Unless the context clearly requires otherwise, throughout the specification and claims, the words "comprising," "having," "including," etc. should be construed to have an inclusive sense rather than an exclusive or exhaustive sense; that is, in the sense of "including but not limited to."

[0224] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0225] "About" and "approximately" refer to values ​​within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which value depends in part on how it is measured or determined (i.e., the limits of the measurement system). For example, "about" can mean within 1 or more than 1 standard deviation. Alternatively, "about" or "substantially comprising" can mean a range of up to 20%, such as between 1% and 15%, between 1% and 10%, between 1% and 5%, between 0.5% and 5%, between 0.5% and 1%, and in this disclosure, each instance of a number or numerical range preceded by the term "about" also includes embodiments of the given number. Unless otherwise stated, when a specific value appears in the application and claims, the meaning of "about" or "substantially comprising" should be assumed to be within an acceptable error range for that specific value.

[0226] The term "and / or," such as "X and / or Y," should be understood to mean "X and Y" or "X or Y" and should be used to provide clear support for both meanings or either meaning.

[0227] In some embodiments, the present disclosure defines:

[0228] Antibody-drug conjugates (ADCs) link antibodies or antibody fragments to biologically active cytotoxins or small molecule drugs with cell-killing activity via a stable chemical linker. These ADCs leverage the antibody's specificity for tumor cell-specific or highly expressed antigens and the high efficacy of the cytotoxin, while avoiding toxic side effects on normal cells. Compared to traditional chemotherapy drugs, ADCs can precisely bind to tumor cells while minimizing their effects on normal cells.

[0229] An antibody drug conjugate "retains its chemical stability" in a pharmaceutical formulation if the antibody drug conjugate shows no significant chemical changes. Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein. Degradation processes that often change the chemical structure of a protein include hydrolysis or truncation (assessed by methods such as size exclusion chromatography and CE-SDS), oxidation (assessed by methods such as peptide mapping in combination with mass spectrometry or MALDI / TOF / MS), deamidation (assessed by methods such as ion exchange chromatography, capillary isoelectric focusing, peptide mapping, isoaspartate measurement), and isomerization (assessed by measuring isoaspartate content, peptide mapping, etc.).

[0230] An antibody drug conjugate "retains its biological activity" in a pharmaceutical formulation if the biological activity of the antibody drug conjugate at a given time is within a predetermined range of the biological activity exhibited when the pharmaceutical formulation is prepared.

[0231] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).

[0232] As used herein, the term "antibody" is used in the broadest sense to encompass various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies; monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), as long as they exhibit the desired antigen-binding activity. An antibody may refer to an immunoglobulin, which is a tetrapeptide chain structure composed of two heavy chains and two light chains connected by interchain disulfide bonds. The amino acid composition and arrangement order of the constant regions of immunoglobulins' heavy chains differ, resulting in different antigenicity. Accordingly, immunoglobulins can be divided into five classes, or so-called immunoglobulin isotypes, namely IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε, respectively. Igs of the same class can be further divided into different subclasses based on differences in the amino acid composition of their hinge regions and the number and position of heavy chain disulfide bonds, such as IgG, which can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are classified as either κ or λ chains based on differences in their constant regions. Each of the five classes of Ig can have either kappa or lambda chains. The approximately 110 amino acids near the N-terminus of both the heavy and light chains of antibodies vary greatly in sequence and constitute the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable and constitute the constant region (C region). The variable region consists of three hypervariable regions (CDRs) and four framework regions (FRs) whose sequences are relatively conserved. These three hypervariable regions determine the specificity of the antibody and are also known as complementarity-determining regions (CDRs). Each light chain variable region (VL) and heavy chain variable region (VH) consists of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDRs of the light chain are referred to as LCDR1, LCDR2, and LCDR3; the three CDRs of the heavy chain are referred to as HCDR1, HCDR2, and HCDR3.

[0233] For the determination or definition of CDRs, the definitive delineation of CDRs and the identification of residues comprising the binding site of the antibody can be accomplished by resolving the structure of the antibody and / or resolving the structure of the antibody-ligand complex. This can be accomplished by any of the various techniques known to those skilled in the art, such as X-ray crystallography. A variety of analytical methods can be used to identify CDRs, including but not limited to the Kabat numbering system, the Chothia numbering system, the AbM numbering system, the IMGT numbering system, contact definitions, and conformational definitions.

[0234] The amino acid sequence boundaries of CDRs can be determined by various well-known schemes, for example: "Kabat" numbering convention (see Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD), "Chothia" numbering convention, "ABM" numbering convention, "contact" numbering convention (see Martin, ACR. Protein Sequence and Structure Analysis of Antibody Variable Domains [J]. 2001) and ImMunoGenTics (IMGT) numbering convention (Lefranc, MP et al., Dev. Comp. Immunol., 27, 55-77 (2003); Front Immunol. 2018 Oct 16; 9: 2278), etc.

[0235] The term "antigen-binding fragment" or "functional fragment" or "antigen-binding portion" refers to one or more fragments of an intact antibody that retains the ability to specifically bind to an antigen. It has been shown that fragments of a full-length antibody can be used to perform the antigen-binding function of an antibody. Exemplary binding fragments encompassed by the term "antigen-binding fragment" include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VH and VL domains of a single arm of an antibody; (v) a dsFv, a stable antigen-binding fragment formed by an interchain disulfide bond between VH and VL; (vi) scFv; (vii) diabodies, bispecific antibodies, and multispecific antibodies comprising fragments such as scFv, dsFv, and Fab.

[0236] The terms "specific binding", "selective binding", "selectively binds" and "specifically binds" refer to the binding of an antibody to a predetermined epitope on an antigen. -8 M, for example, less than approximately 10 -9 M, 10 - 10 M, 10 -11 Binds with an affinity (KD) of M or less.

[0237] The term "KD" refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. Typically, the antibodies of the present disclosure exhibit dissociation equilibrium constants of less than about 10-7 M, for example, less than about 10-7 M. -8 M, 10 -9 M or 10 -10 The IL-5 binding protein binds to IL-5 with a dissociation equilibrium constant (KD) of M or less, e.g., as determined using surface plasmon resonance (SPR) technology in a BIACORE instrument.

[0238] "Identity" refers to the sequence similarity between two polynucleotide sequences or between two polypeptides. When a position in the two compared sequences is occupied by the same base or amino acid monomer subunit, for example, if every position in two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percentage homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100. For example, when the sequences are optimally aligned, if 6 out of 10 positions in the two sequences match or are homologous, then the two sequences are 60% homologous; if 95 out of 100 positions in the two sequences match or are homologous, then the two sequences are 95% homologous. Typically, when two sequences are aligned, the comparison is made to give the maximum percentage identity. For example, the comparison can be performed using the BLAST algorithm, where the parameters of the algorithm are selected to give the maximum match between each sequence over the entire length of each reference sequence. The following references relate to the BLAST algorithm commonly used for sequence analysis: BLAST ALGORITHMS: Altschul, SF et al., (1990) J. Mol. Biol. 215: 403-410; Gish, W. et al., (1993) Nature Genet. 3: 266-272; Madden, TL et al., (1996) Meth. Enzymol. 266: 131-141; Altschul, SF et al., (1997) Nucleic Acids Res. 25: 3389-3402; Zhang, J. et al., (1997) Genome Res. 7: 649-656. Other conventional BLAST algorithms, such as those provided by NCBI BLAST, are also well known to those skilled in the art.

[0239] "Administering" and "treating" as applied to an animal, a human, a laboratory subject, a cell, a tissue, an organ or a biological fluid, refers to the contacting of an exogenous drug, therapeutic agent, diagnostic agent or composition with an animal, a human, a subject, a cell, a tissue, an organ or a biological fluid. "Administering" and "treating" can refer to, for example, therapeutic, pharmacokinetics, diagnostics, research and experimental procedures. Treatment of cells includes contacting an agent with a cell, and contacting an agent with a fluid, wherein the fluid is in contact with the cell. "Administering" and "treating" also mean treating, for example, a cell in vitro and ex vivo, by an agent, a diagnostic, a binding composition or by another cell. "Treatment" as applied to a human, veterinary or research subject, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.

[0240] "Treatment" means administering an internal or external therapeutic agent, such as a composition comprising any of the binding compounds of the present disclosure, to a patient who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of the disease in the patient or population being treated, to induce regression of such symptoms or to inhibit the progression of such symptoms to any clinically measurable degree. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") can vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether the symptoms of the disease have been alleviated can be assessed by any clinical test method commonly used by a physician or other health care professional to assess the severity or progression of the symptoms. Although embodiments of the present disclosure (e.g., methods of treatment or articles of manufacture) may not be effective in alleviating every symptom of the target disease, they should alleviate the target disease symptoms in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t-test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.

[0241] An "effective amount" encompasses an amount sufficient to ameliorate or prevent the symptoms or conditions of a medical condition. An effective amount also means an amount sufficient to permit or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects.

[0242] The terms "subject" and "patient" refer to mammals, particularly primates, and especially humans.

[0243] The "combination" described in the present disclosure is a mode of administration, which refers to the administration of at least one dose of an anti-HER3 antibody drug conjugate and at least one dose of a VEGF signaling pathway inhibitor within a certain time period, wherein both drugs show a pharmacological effect. The time period can be within a dosing cycle, for example, within 4 weeks, within 3 weeks, within 2 weeks, within 1 week, or within 24 hours, or within 12 hours. The anti-HER2 antibody drug conjugate or a pharmaceutically acceptable salt thereof and the VEGF signaling pathway inhibitor can be administered simultaneously or sequentially. This period includes treatments in which the anti-HER3 antibody drug conjugate and the VEGF signaling pathway inhibitor are administered by the same route of administration or different routes of administration, or the anti-HER2 antibody drug conjugate and the VEGF signaling pathway inhibitor are administered by the same route of administration or different routes of administration. The combined administration mode described in the present disclosure is selected from simultaneous administration, independent formulation and co-administration, or independent formulation and sequential administration.

[0244] In the anti-HER3 antibody drug conjugates disclosed herein, "n" refers to the average number of cytotoxic drugs loaded on each antibody or antigen-binding fragment thereof in the antibody drug conjugate molecule, and can also be expressed as the ratio of the amount of drug to the amount of antibody, which is the average number of drugs per ADC molecule after the coupling reaction as determined by hydrophobic chromatography (HIC) mass spectrometry.

[0245] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity. DETAILED DESCRIPTION

[0246] The present disclosure is further described below with reference to the following examples, but these examples are not intended to limit the scope of the present disclosure. Experimental methods in the examples herein where specific conditions are not specified generally follow conventional conditions, such as those in the Cold Spring Harbor Laboratory's "Antibody Techniques Laboratory Manual" and "Molecular Cloning Manual," or according to the conditions recommended by the raw material or product manufacturer. Reagents where the specific source is not specified are commercially available.

[0247] Example 1. Preparation of anti-HER3 antibody drug conjugates

[0248] The anti-HER3 antibody drug conjugates are Example 3-1 (n=4.19), Example 3-2 (n=2.91), and Example 3-3 (n=7.27) in WO2022078425A1 (incorporated herein by reference in its entirety), and have the following structures:

[0249] The structure of the anti-HER3 antibody drug conjugate is abbreviated as the following structural formula ADC-1:

[0250] Here, n (DAR value) is about 4.0, which is equivalent to 4.0±0.4.

[0251] The HER3 antibody is derived from the antibody HER3-29 of WO2022078425A1, and the CDR sequences are shown in Table 1. The full length of the heavy chain of the antibody HER3-29 is shown in SEQ ID NO: 9, and the full length of the light chain is shown in SEQ ID NO: 10.

[0252] ADC-1 was formulated into an injection (sterile powder for injection) with a specification of 100 mg / bottle.

[0253] Example 2. Study on the safety, tolerability and efficacy of ADC-1 for injection combined with anti-tumor therapy in patients with advanced solid tumors

[0254] 1. Trial Drug

[0255] 1) ADC-1 prepared in Example 1.

[0256] 2) Anti-VEGF antibody (bevacizumab), the heavy chain sequence of which is SEQ ID NO: 19, and the light chain sequence of which is SEQ ID NO: 20.

[0257] 2. Enrollment of subjects

[0258] 1) Age range: 18 to 75 years old (inclusive), gender is not limited;

[0259] 2) Part C1: Subjects with unresectable locally advanced or metastatic non-squamous non-small cell lung cancer confirmed by histology or cytology; Part C2: Subjects with other locally advanced metastatic solid tumors confirmed by histology or cytology;

[0260] 3) Part C: Relapse or progression after standard treatment, or no standard treatment options, or standard treatment is not currently applicable;

[0261] 4) at least one measurable tumor lesion according to RECIST v1.1 (subjects with only non-target lesions are allowed to be enrolled in stage IB);

[0262] 5) All enrolled subjects must provide tumor tissue samples for HER3 expression and other tests (subjects who are unable to provide tumor tissue samples are allowed to be enrolled in the Phase IB stage). The requirements for tumor tissue samples are: neutral formalin-fixed, paraffin-embedded [FFPE] tissue blocks or at least 6 unstained tumor tissue sections, fresh or archived, with fresh samples being preferred. Subjects who are unable to provide freshly obtained tissues may provide archived tumor tissue samples within 12 months before the first study treatment. For subjects who are unable to provide tumor tissue samples that meet the above requirements, it is necessary to discuss with the sponsor to determine whether to enroll;

[0263] 6) ECOG performance score 0-1;

[0264] 7) Expected survival time ≥12 weeks;

[0265] 8. Have adequate bone marrow and organ function. The following test results must be completed within 7 days before the first study treatment:

[0266] a) Routine blood test (no blood transfusion or hematopoietic stimulating factor treatment within 14 days before the test): neutrophil count (ANC) ≥ 1.5 × 10 9 / L(1,500 / mm 3 ), platelets ≥100×10 9 / L(100,000 / mm 3 ), hemoglobin (Hgb) ≥9.0 g / dL (90 g / L);

[0267] b) Liver function tests (no liver-protective medication within 7 days before the test): alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (for subjects with confirmed liver metastasis, ALT and AST ≤ 5 × ULN), total bilirubin ≤ 1.5 × ULN (for subjects with confirmed Gilbert syndrome, total bilirubin ≤ 3 mg / dL);

[0268] c) Renal function test: serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL / min (using the Cockcroft-Gault formula);

[0269] d) Coagulation function test: prothrombin time and partial thromboplastin time ≤ 1.5×ULN.

[0270] 3. Dosage regimen

[0271] Part C is a clinical trial evaluating ADC-1 in combination with bevacizumab for the treatment of locally advanced / metastatic non-squamous NSCLC and other advanced solid tumors. The study includes a screening phase, a treatment phase, and a follow-up phase. The treatment phase includes Phase IB and Phase II trials.

[0272] According to the tumor type, the patients are divided into Part C1 and Part C2: Part C1 is locally advanced or metastatic non-squamous non-small cell lung cancer, and Part C2 is other locally advanced / metastatic solid tumors.

[0273] In the Phase IB stage, the dose exploration adopts the "i3+3" design with three pre-set dose groups:

[0274] Dose group 1: ADC-1 8.0 mg / kg Q3W plus bevacizumab 7.5 mg / kg Q3W;

[0275] Dose group 2: ADC-1 8.0 mg / kg Q3W plus bevacizumab 15 mg / kg Q3W;

[0276] Dose group 3: ADC-1 7.0 mg / kg Q3W combined with bevacizumab 7.5 mg / kg Q3W.

[0277] The treatment cycle is 21 days. ADC-1 is administered by intravenous drip every 3 weeks, and bevacizumab is administered by intravenous drip every 3 weeks.

[0278] Phase II: Enrolled subjects receive the recommended dose of ADC-1 combined with bevacizumab until disease progression or meet other discontinuation criteria.

[0279] 4. Results

[0280] As of the data collection date, a total of 19 patients were enrolled. Details are shown in Table 2.

[0281] Table 2. Subjects' information

[0282] *Due to data entry delay, 2 subjects have not yet been entered

[0283] 2) Effectiveness data

[0284] As shown in Table 3, at the highest dose of ADC-1 (8.0 mg / kg) combined with bevacizumab (15 mg / kg), the objective response rate (ORR) was 57.1% and the disease control rate (DCR) was 100.0%. The ORR for ADC-1 (8.0 mg / kg) combined with bevacizumab (7.5 mg / kg) was 63.6% and the DCR was 100.0%. The ADC-1 combined with bevacizumab regimen demonstrated excellent therapeutic efficacy.

[0285] Table 3. Efficacy evaluation

[0286] *Due to data entry delay, 2 subjects have not yet been entered

[0287] 3) Safety evaluation

[0288] In the ADC-1 8.0 mg / kg plus bevacizumab 15 mg / kg (N=7), two patients (28.6%) reported grade ≥ 3 TRAEs, including one case each of decreased neutrophil count and hypertension. In the ADC-1 8.0 mg / kg plus bevacizumab 7.5 mg / kg (N=11), seven patients (63.6%) reported grade ≥ 3 treatment-related adverse events (TRAEs).

Claims

1. Any of the following uses (1) to (5): (1) Use of an anti-HER3 antibody-drug conjugate combined with a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors; (2) Use of a combination of an anti-HER3 antibody-drug conjugate and a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors; (3) Use of the pharmaceutical composition in the preparation of a drug for treating tumors; wherein: The pharmaceutical composition comprises an anti-HER3 antibody-drug conjugate; and a VEGF signaling pathway inhibitor; (4) an anti-HER3 antibody-drug conjugate for use in treating a subject with a tumor, wherein the subject is also administered a VEGF signaling pathway inhibitor; (5) A VEGF signaling pathway inhibitor for use in treating a subject with a tumor, wherein the subject is also administered an anti-HER3 antibody drug conjugate; Wherein, the anti-HER3 antibody drug conjugate has a structure as shown in the following formula: Wherein: n is 1 to 8, and Pc is an anti-HER3 antibody.

2. The use according to claim 1, wherein The tumor is non-small cell lung cancer; preferably non-squamous cell non-small cell lung cancer.

3. The use according to claim 2, wherein The tumor is selected from: Locally advanced or metastatic non-small cell lung cancer, or, Locally advanced or metastatic non-squamous non-small cell lung cancer.

4. The use according to claim 1, wherein: (1) the tumor is an EGFR mutated tumor, preferably an EGFR mutated non-small cell lung cancer; and / or, (2) the subject with the tumor has a history of treatment with a tyrosine kinase inhibitor (TKI), preferably non-small cell lung cancer that has failed EGFR-TKI treatment; Preferably, the EGFR mutant tumor is an EGFR mutant tumor that has failed tyrosine kinase inhibitor (TKI) treatment.

5. The use according to any one of claims 1 to 4, wherein The VEGF signaling pathway inhibitor is an anti-VEGF antibody; preferably, the anti-VEGF antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13, respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16, respectively.

6. The use according to claim 5, wherein The anti-VEGF antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence as shown in SEQ ID NO: 17 or having at least 90% identity thereto, and the VL comprises an amino acid sequence as shown in SEQ ID NO: 18 or having at least 90% identity thereto; Preferably, the anti-VEGF antibody comprises a heavy chain comprising an amino acid sequence as shown in SEQ ID NO: 19 or having at least 90% identity thereto, and a light chain comprising an amino acid sequence as shown in SEQ ID NO: 20 or having at least 90% identity thereto.

7. The use according to claim 5 or 6, wherein The anti-VEGF antibody is administered at a dose of about 1.0 mg / kg to about 30 mg / kg, about 2.0 mg / kg to about 25 mg / kg, about 2.0 mg / kg to about 20 mg / kg, about 2.0 mg / kg to about 19 mg / kg, about 2.0 mg / kg to about 18 mg / kg, about 2.0 mg / kg to about 17 mg / kg, or about 2.0 mg / kg to about 16 mg / kg, Preferably, about 2.0 mg / kg, about 3.0 mg / kg, about 4.0 mg / kg, about 5.0 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7.0 mg / kg, about 7.5 mg / kg, 8.0 mg / kg, 8.5 mg / kg, about 9.0 mg / kg, about 10.0 mg / kg, about 11.0 mg / kg, about 12.0 mg / kg, about 13.0 mg / kg, about 14.0 mg / kg, about 14.5 mg / kg, about 15.0 mg / kg, about 16.0 mg / kg, about 16.5 mg / kg, about 17.0 mg / kg, about 18.0 mg / kg, about 19.0 mg / kg, about 20.0 mg / kg; The anti-VEGF antibody is administered once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every 12 weeks; preferably once every three weeks.

8. The use according to any one of claims 1 to 7, wherein The anti-HER3 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; Preferably, the VH comprises an amino acid sequence as shown in SEQ ID NO:7, or having at least 90% identity thereto, and the VL comprises an amino acid sequence as shown in SEQ ID NO:8, or having at least 90% identity thereto; More preferably, the anti-HER3 antibody comprises a heavy chain comprising an amino acid sequence as shown in SEQ ID NO:9 or having at least 90% identity thereto, and a light chain comprising an amino acid sequence as shown in SEQ ID NO:10 or having at least 90% identity thereto.

9. The use according to any one of claims 1 to 8, wherein The anti-HER3 antibody drug conjugate is administered at a dosage of about 0.1 mg / kg to about 20 mg / kg, about 1.0 mg / kg to about 20 mg / kg, about 1.0 mg / kg to about 13.5 mg / kg, about 1.0 mg / kg to about 12 mg / kg, about 1.5 mg / kg to about 10.5 mg, about 1.5 mg / kg to about 9.0 mg / kg; about 1.5 mg / kg to about 8.5 mg / kg, or about 1.5 mg / kg to about 8.0 mg / kg; Preferably about 1.0 mg / kg, about 1.5 mg / kg, about 3.0 mg / kg, about 4.5 mg / kg, about 5.0 mg / kg, about 5.5 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7.0 mg / kg, about 7.5 mg / kg, about 8.0 mg / kg, about 8.5 mg / kg, about 9.0 mg / kg, about 10.5 mg / kg, about 12 mg / kg, or about 13.5 mg / kg; The administration frequency of the anti-HER3 antibody drug conjugate is once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every 12 weeks; preferably once every two weeks, or once every three weeks.

10. The use according to any one of claims 1 to 9, wherein The dosage of the anti-HER3 antibody drug conjugate is about 0.1 mg / kg to about 20 mg / kg, and the administration frequency is once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 6 weeks, once every 8 weeks, once every 10 weeks, or once every 12 weeks; and / or The VEGF signaling pathway inhibitor is administered at a dosage of about 1.0 mg / kg to about 30 mg / kg, and the administration frequency is once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 6 weeks, once every 8 weeks, once every 10 weeks, or once every 12 weeks; Preferably, The dosage of the anti-HER3 antibody drug conjugate is about 1.5 mg / kg to about 9.0 mg / kg, and the dosage frequency of the anti-HER3 antibody drug conjugate is once every 3 weeks; and, the dosage of the VEGF signaling pathway inhibitor is about 2 mg / kg to about 20 mg / kg, and the dosage frequency is once every 3 weeks.

11. A method for treating a subject having a tumor, comprising administering to the subject: an anti-HER3 antibody drug conjugate, and a VEGF signaling pathway inhibitor; Preferably, the anti-HER3 antibody-drug conjugate is as defined in any one of claims 1 to 9, and the VEGF signaling pathway inhibitor is an anti-VEGF antibody as defined in any one of claims 5 to 7; Preferably, the tumor is non-small cell lung cancer; more preferably, locally advanced or metastatic non-small cell lung cancer; Preferably, the tumor is an EGFR mutated tumor; more preferably, it is an EGFR mutated non-small cell lung cancer.

12. A pharmaceutical composition comprising an anti-HER3 antibody-drug conjugate and a VEGF signaling pathway inhibitor; The anti-HER3 antibody drug conjugate has a structure as shown in the following formula: in: n is 1 to 8, Pc is an anti-HER3 antibody; Preferably, the VEGF signaling pathway inhibitor is preferably an anti-VEGF antibody; Preferably, the anti-HER3 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively, and the VL comprising LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively; more preferably, the VH comprises an amino acid sequence as shown in SEQ ID NO:7 or having at least 90% identity thereto, and the VL comprises an amino acid sequence as shown in SEQ ID NO:8 or having at least 90% identity thereto; More preferably, the anti-HER3 antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence as shown in SEQ ID NO: 9 or having at least 90% identity thereto, and the light chain comprises an amino acid sequence as shown in SEQ ID NO: 10 or having at least 90% identity thereto; Preferably, the anti-VEGF antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13, respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, respectively; More preferably, the anti-VEGF antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence as shown in SEQ ID NO: 17 or having at least 90% identity thereto, and the VL comprises an amino acid sequence as shown in SEQ ID NO: 18 or having at least 90% identity thereto; More preferably, the anti-VEGF antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence as shown in SEQ ID NO: 19 or having at least 90% identity thereto, and the light chain comprises an amino acid sequence as shown in SEQ ID NO: 20 or having at least 90% identity thereto; Preferably, the pharmaceutical composition is used to treat tumors, preferably for treating non-small cell lung cancer; more preferably for treating locally advanced or metastatic non-small cell lung cancer; preferably, the tumor is an EGFR mutated tumor; more preferably, it is an EGFR mutated non-small cell lung cancer.

13. The pharmaceutical composition according to claim 12, wherein: i-1) the dosage of the anti-HER3 antibody drug conjugate is about 0.1 mg / kg to about 20 mg / kg; Preferably, about 1.0 mg / kg to about 20 mg / kg, about 1.0 mg / kg to about 13.5 mg / kg, about 1.0 mg / kg to about 12 mg / kg, about 1.5 mg / kg to about 10.5 mg, about 1.5 mg / kg to about 9.0 mg / kg; about 1.5 mg / kg to about 8.5 mg / kg, about 1.5 mg / kg to about 8.0 mg / kg; More preferably about 1.0 mg / kg, about 1.5 mg / kg, about 3.0 mg / kg, about 4.5 mg / kg, about 5.0 mg / kg, about 5.5 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7.0 mg / kg, about 7.5 mg / kg, about 8.0 mg / kg, about 8.5 mg / kg, about 9.0 mg / kg, about 10.5 mg / kg, about 12 mg / kg, or about 13.5 mg / kg; i-2) The administration frequency of the anti-HER3 antibody drug conjugate is once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, once every ten weeks, or once every 12 weeks; preferably once every two weeks, or once every three weeks; and / or, ii-1) the VEGF signaling pathway inhibitor is administered at a dosage of about 1.0 mg / kg to about 30 mg / kg, Preferably, about 2.0 mg / kg to about 25 mg / kg, about 2.0 mg / kg to about 20 mg / kg, about 2.0 mg / kg to about 19 mg / kg, about 2.0 mg / kg to about 18 mg / kg, about 2.0 mg / kg to about 17 mg / kg, about 2.0 mg / kg to about 16 mg / kg, More preferably, about 5.0 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7.0 mg / kg, about 7.5 mg / kg, 8.0 mg / kg, 8.5 mg / kg, about 9.0 mg / kg, about 9.5 mg / kg, about 10.0 mg / kg, about 10.5 mg / kg, about 11.0 mg / kg, about 11.5 mg / kg, about 12.0 mg / kg, about 12.5 mg / kg, about 13.0 mg / kg, about 13.5 mg / kg, about 14.0 mg / kg, about 14.5 mg / kg, about 15.0 mg / kg, about 15.5 mg / kg, about 16.0 mg / kg; ii-2) The administration frequency of the VEGF signaling pathway inhibitor is once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 6 weeks, once every 8 weeks, once every 10 weeks, or once every 12 weeks; preferably once every 3 weeks.

Images